Manny Katsetos, MD
Interventional Cardiology · New Britain, CTNPI 1609823368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,519 and has fallen 57.4% since, to $647 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.
Across 345 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Pfizer$960
- Novartis$713
- Boston Scientific$681
- Abbott$420
- Amarin Pharma, Inc.$342
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$6,80097%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 89 | $1,339 |
| Pfizer | 52 | $960 |
| Novartis | 44 | $713 |
| Boston Scientific | 22 | $681 |
| Abbott | 19 | $420 |
| Amarin Pharma, Inc. | 23 | $342 |
| Alnylam Pharmaceuticals Inc. | 5 | $219 |
| Vifor Pharma, Inc. | 1 | $200 |
| Novo Nordisk | 4 | $187 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $174 |
| Esperion Therapeutics, Inc. | 8 | $173 |
| AstraZeneca | 10 | $166 |
| Philips North America LLC | 2 | $166 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $135 |
| Amgen | 5 | $130 |
| Medtronic | 2 | $103 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $103 |
| Kowa Pharmaceuticals America, Inc. | 7 | $103 |
| E.r. Squibb & Sons, L.L.C. | 6 | $96 |
| Impulse Dynamics (USA) Inc. | 4 | $93 |
| Heartflow, Inc. | 5 | $81 |
| Lilly USA, LLC | 3 | $74 |
| Lexicon Pharmaceuticals, Inc. | 3 | $71 |
| Akcea Therapeutics, Inc. | 3 | $65 |
| Merck | 3 | $53 |
| Boehringer Ingelheim | 2 | $41 |
| Astellas Pharma US Inc | 2 | $33 |
| Scpharmaceuticals Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| AbbVie | 1 | $19 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,005 in reported general payments places this provider in the 50th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 571 | $680,037 |
| XareltoRivaroxaban | 273 | $304,416 |
| EntrestoSacubitril/Valsartan | 164 | $279,707 |
| Repatha SureclickEvolocumab | 148 | $131,373 |
| FuroscixFurosemide | 15 | $103,471 |
| JardianceEmpagliflozin | 57 | $94,961 |
| BrilintaTicagrelor | 59 | $65,754 |
| MultaqDronedarone Hcl | 41 | $56,507 |
| FarxigaDapagliflozin Propanediol | 20 | $23,834 |
| Metoprolol Succinate | 1,355 | $15,631 |
| Ranolazine ErRanolazine | 115 | $15,118 |
| Praluent PenAlirocumab | 13 | $14,144 |
| VascepaIcosapent Ethyl | 19 | $12,647 |
| Atorvastatin Calcium | 1,085 | $9,108 |
| Ezetimibe | 332 | $5,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $960 | $680,037571 claims |
| Johnson & JohnsonXarelto | $1,339 | $304,416273 claims |
| NovartisEntresto | $713 | $279,707164 claims |
| Scpharmaceuticals Inc.Furoscix | $31 | $103,47115 claims |
| Boehringer IngelheimJardiance | $41 | $94,96157 claims |
| AstraZenecaBrilinta, Farxiga | $166 | $89,58779 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in New Britain
- Wael ElmallahNew Britain$9K
- Robert BorkowskiNew Britain$8K
- Aaron BriceNew Britain$6K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.